Last month marked the fourth anniversary of Patent Trial and Appeal Board proceedings becoming available. While early cases suggested that the Board would be a graveyard for patents, in the past year a more nuanced picture has emerged. Michael Loney identifies 10 issues to watch
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Richard de Bodo, who had a lengthy career at international firms, shares how he will address client needs and praises the unique offerings of smaller firms
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Azhar Sadique and Kane Ridley, who founded the London office in 2023, are now both working in legal tech and AI-related roles, while another UK-based lawyer has also left